Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Net Cash Flow (2022 - 2025)

Taysha Gene Therapies' Net Cash Flow history spans 4 years, with the latest figure at -$15.4 million for Q3 2025.

  • For Q3 2025, Net Cash Flow fell 2.4% year-over-year to -$15.4 million; the TTM value through Sep 2025 reached $139.7 million, up 2207.38%, while the annual FY2024 figure was -$4.9 million, 108.75% down from the prior year.
  • Net Cash Flow for Q3 2025 was -$15.4 million at Taysha Gene Therapies, down from $196.2 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $196.2 million in Q2 2025 and bottomed at -$52.5 million in Q1 2022.
  • The 4-year median for Net Cash Flow is -$18.7 million (2024), against an average of $9.9 million.
  • The largest YoY upside for Net Cash Flow was 473.27% in 2023 against a maximum downside of 138.03% in 2023.
  • A 4-year view of Net Cash Flow shows it stood at $53.6 million in 2022, then plummeted by 138.03% to -$20.4 million in 2023, then increased by 8.46% to -$18.7 million in 2024, then grew by 17.34% to -$15.4 million in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Net Cash Flow are -$15.4 million (Q3 2025), $196.2 million (Q2 2025), and -$22.4 million (Q1 2025).